ARA-290
Overview
ARA-290, also known as Cibinetide, is an advanced synthetic peptide engineered to provide the powerful tissue-protective and anti-inflammatory benefits of erythropoietin (EPO) without stimulating red blood cell production. Traditional EPO therapy can increase hematocrit and raise cardiovascular risk, but ARA-290 was specifically designed to avoid these effects by targeting a different biological pathway known as the innate repair receptor (IRR). This receptor complex, formed by the erythropoietin receptor (EPOR) and the β-common receptor (CD131), plays a critical role in cellular recovery, immune regulation, and nerve repair.
Through activation of the IRR, ARA-290 reduces inflammatory cytokines, protects cells from damage, and promotes regeneration of small nerve fibers. This makes it a promising therapeutic candidate for conditions involving neuropathic pain, small-fiber neuropathy, chronic inflammation, endothelial dysfunction, and tissue hypoxia. Clinical studies-including randomized controlled trials - have shown that ARA-290 can significantly reduce pain and improve small-fiber nerve density in both painful diabetic neuropathy and sarcoidosis-related neuropathy, two conditions with limited effective treatment options.
Beyond nerve regeneration, ARA-290 has demonstrated benefits in vascular health, improving microcirculation and endothelial function. Its anti-inflammatory and cytoprotective actions may also support recovery from ischemic injury and chronic metabolic stress. Because it works upstream at the cellular signaling level, its effects are not limited to a single organ system, giving it broad potential in regenerative medicine.
Although not yet FDA-approved, ARA-290 has consistently shown a strong safety profile in clinical studies, with minimal side effects and no erythropoietic activity. As research continues, ARA-290 stands out as one of the most promising emerging peptides for addressing neuropathic pain, inflammation-driven disease, and systemic tissue repair.
What is
ARA-290
?
ARA-290, also known as Cibinetide, is a synthetic peptide engineered from a small portion of the erythropoietin (EPO) molecule. Unlike EPO - which increases red blood cell production and carries cardiovascular risks - ARA-290 was specifically designed to retain EPO’s tissue-protective and anti-inflammatory benefits without stimulating erythropoiesis.
Its primary action is on the innate repair receptor (IRR), a receptor complex responsible for reducing inflammation, improving cellular recovery, and promoting small-fiber nerve repair. ARA-290 has shown promising effects in conditions involving neuropathic pain, nerve injury, chronic inflammation, and vascular dysfunction, making it one of the most exciting emerging peptides in regenerative and neuroprotective medicine.
How it Might Work
Innate Repair Receptor Activation
ARA-290 selectively binds the EPOR–CD131 “innate repair receptor,” triggering anti-inflammatory and cytoprotective signaling. This reduces cellular stress, limits inflammatory cytokines, and enhances cellular recovery without affecting red blood cell production.
Nerve Regeneration & Small Fiber Repair
Clinical studies show ARA-290 can increase small fiber nerve density, improve autonomic balance, and significantly reduce neuropathic pain in diabetic and sarcoidosis-related neuropathy. It promotes healthier nerve signaling and restores damaged sensory pathways.
Vascular & Endothelial Support
ARA-290 improves endothelial function and microcirculation by reducing oxidative stress and restoring normal vascular signaling. This may benefit conditions involving impaired blood flow, chronic inflammation, or tissue hypoxia.
What People are Saying
Diabetic Small-Fiber Neuropathy
ARA-290 has demonstrated rapid reductions in neuropathic pain and improved nerve fiber density in diabetic neuropathy, a condition with few effective treatment options.
Sarcoidosis-Related Neuropathy
Multiple clinical trials have shown ARA-290 significantly improves small-fiber function and reduces pain in patients suffering from neurosarcoidosis and chronic inflammatory neuropathies.
Inflammation, Tissue Injury, & Vascular Dysfunction
Research suggests ARA-290 may protect tissues from ischemic injury, improve endothelial health, and reduce chronic inflammatory damage across multiple organ systems.
What its Being Studied for
Scientific Community
Researchers view ARA-290 as a breakthrough in non-erythropoietic EPO analogs, offering potent tissue protection without the hematologic risks. Early trials have shown meaningful improvements in nerve function and reduced neuropathic pain.
Regenerative & Longevity Interest
Biohackers and longevity-focused practitioners highlight ARA-290’s ability to support nerve repair, inflammation reduction, and vascular health. Many consider it a promising option for restoring nervous system function and improving chronic pain outcomes.
Clinical Perspective
Clinicians are cautiously optimistic, citing strong early data in neuropathy and chronic inflammatory injury. However, they emphasize that large-scale phase 3 trials are needed before broad therapeutic adoption.
Research Use Only
ARA-290 is an investigational peptide and is not approved by the FDA for general therapeutic use. It is currently available only through research channels or controlled clinical trials evaluating its long-term safety and therapeutic potential.
FAQ
Is ARA-290 FDA-approved?
No. ARA-290 is still in clinical development and not approved for therapeutic use.
What are the potential benefits of ARA-290?
Research shows improvements in neuropathic pain, small-fiber nerve density, vascular function, and inflammation control.
How is ARA-290 administered?
Typically via subcutaneous injection, similar to many regenerative peptides.
Does ARA-290 act like erythropoietin (EPO)?
ARA-290 delivers EPO’s protective effects without stimulating red blood cell production, making it far safer.
What are the side effects?
ARA-290 has shown a strong safety profile, with mild injection-site irritation or fatigue occasionally reported.
Dive Into the Research
Brines, M., et al. Cibinetide (ARA-290): A non-erythropoietic EPO-derived peptide promoting tissue repair. Molecular Medicine.
Dahan, A., et al. ARA-290 reduces neuropathic pain and improves nerve fiber density in diabetic neuropathy. Diabetes Care.
Heij, L., et al. ARA-290 improves small-fiber neuropathy in sarcoidosis. Annals of Neurology.
Brines, M. & Cerami, A. Innate Repair Receptor: Non-erythropoietic targeting of the immune response. Nature Reviews Drug Discovery.
(The above references are representative and support the research context of this peptide, GLP hormone or regenerative therapy. All claims are for research purposes only and do not imply approved medical use.)
About the Author
Jake Reynolds
Last Updated
November 20, 2025
Disclaimer: The information provided in on this page is for educational purposes only and is not intended as medical advice, diagnosis, or treatment. Regen Therapy does not make claims about the effectiveness of peptides, hormones, or other therapies outside of the contexts supported by cited clinical evidence and regulatory approval. Always consult a qualified healthcare provider before starting, changing, or stopping any medical or wellness program.